引用本文
  • 罗轶玮,符雪莲,马钻,等.氨基酸转运蛋白SLC6A14在大肠癌中的表达特征及其促癌功能研究[J].同济大学学报(医学版),2021,42(1):28-34.    [点击复制]
  • LUO Yi-wei,FU Xue-lian,MA Zuan,et al.Expression of amino acid transporter SLC6A14 and its effect on cell proliferation in colorectal cancer[J].同济大学学报(医学版),2021,42(1):28-34.   [点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 489次   下载 548 本文二维码信息
码上扫一扫!
氨基酸转运蛋白SLC6A14在大肠癌中的表达特征及其促癌功能研究
罗轶玮,符雪莲,马钻,王恺京,李芳漪,陆英
0
(同济大学附属东方医院全科教研室,上海200120;同济大学附属东方医院转化医学研究中心,上海200120)
摘要:
目的研究氨基酸转运蛋白SLC6A14在大肠癌中的表达特征及其促进大肠癌细胞生长的作用。方法采用实时定量荧光PCR(real-time PCR)检测35对大肠癌及癌旁组织中SLC6A14 mRNA的表达水平;Western印迹法检测SLC6A14在大肠癌细胞株HT-29和SW620中的蛋白表达;免疫组化法检测108例大肠癌组织中SLC6A14的蛋白表达并分析其表达强度与患者临床特征的相关性;MTT法和流式细胞术分别检测下调或抑制SLC6A14对大肠癌细胞生长及凋亡的影响。结果SLC6A14 mRNA在大肠癌组织中的表达水平是癌旁组织的(3.98±1.1)倍(P<0.05);SLC6A14在大肠癌细胞株HT-29和SW620中的蛋白表达明显高于肝癌细胞株Huh7,分别是其(4.31±1.46)倍和(3.14±0.93)倍,均P<0.05。免疫组化结果显示SLC6A14在Ⅳ期癌组织中的蛋白表达强度(135.36±24.28)明显高于Ⅰ、Ⅱ、Ⅲ期癌组织(分别为42.87±26.50、75.67±30.25、101.32±32.47,均P<0.001),但其表达水平在不同年龄、性别和肿瘤大小中的表达差异未见统计学意义(P>0.05)。通过siRNA下调SLC6A14在HT-29和SW620中的表达或抑制剂α-MT后,MTT结果显示大肠癌细胞增殖明显减慢,流式细胞术检测Annexin-Ⅴ+/PI-细胞凋亡明显增加,P<0.05。结论SLC6A14在大肠癌组织和细胞株中表达增加并促进癌细胞生长,是大肠癌治疗的潜在靶点。
关键词:  氨基酸转运蛋白  SLC6A14  大肠癌  增殖  凋亡
DOI:10.12289/j.issn.1008-0392.20484
投稿时间:2020-11-11
基金项目:上海市浦东新区科委创新基金(PKJ2016-Y63);国家自然科学基金青年项目(82001725);江西省自然科学基金面上项目(20181BAB205033)
Expression of amino acid transporter SLC6A14 and its effect on cell proliferation in colorectal cancer
LUO Yi-wei,FU Xue-lian,MA Zuan,WANG Kai-jing,LI Fang-yi,LU Ying
(Dept. of General Practice, East Hospital, Tongji University School of Medicine, Shanghai 200120, China;Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China)
Abstract:
ObjectiveTo investigate the expression of amino acid transporter SLC6A14 and its effect on cell proliferation in colorectal cancer (CRC). MethodsThe expression of SLC6A14 mRNA in 35 paired colorectal cancer and pericancerous tissue samples was detected by real-time RT-PCR (qRT-PCR). The expression of SLC6A14 protein in tissue samples of 108 CRC patients was determined by immunohistochemistry, and the correlation between the intensity of SLC6A14 expression and the clinical characteristics of patients was analyzed. The expression of SLC6A14 protein in human colorectal cancer HT-29, SW620 cells and human liver cancer Huh7 cells was detected by Western blotting. HT-29 and SW620 cells were treated with siRNA or α-MT to down-regulating SLC6A14 expression; and the cell proliferation and apoptosis were detected by MTT method and flow cytometry. ResultsThe expression of SLC6A14 mRNA in colorectal cancer tissues was 3.98±1.1 times higher than that in pericancerous tissues (P<0.05). The expression of SLC6A14 protein in HT-29 and SW620 cells was 4.31±1.46 and 3.14±0.93 times higher than that in Huh7 cells (P<0.05). Immunohistochemical results showed that the expression intensity of SLC6A14 in stage Ⅳ of CRC (135.36±24.28) was significantly higher than that in stage Ⅰ, Ⅱ and Ⅲ (42.87±26.50, 75.67±30.25, 101.32±32.47, respectively) (P<0.001), but there was no significant difference in the expression level of SLC6A14 among patients with different age, gender and tumor size (P>0.05). After HT-29 and SW620 cells were treated with SLC6A14-siRNA or inhibitor α- MT at three different concentrations, the cell proliferation was significantly reduced, and the apoptosis was significantly increased (P<0.05). ConclusionSLC6A14 is upregulated in colorectal cancer and is involved in proliferation of CRC cells, indicating that it may be a potential therapeutic target for CRC.
Key words:  amino acid transporter  SLC6A14  colorectal cancer  proliferation  apoptosis

您是第4970593位访问者
版权所有《同济大学学报(医学版)》编辑部
主管单位:教育部 主办单位:同济大学
地  址: 上海四平路1239号 邮编:200092 电话:021-65980705 E-mail: yxxb@tongji.edu.cn
本系统由北京勤云科技发展有限公司设计